PROFESSIONAL

ACTFusion™

New Progress in Tumor Treatment-Finding biomarker in 182 fusion transcripts 

The fusion genes are hybrid genes form as a result of chromosomal rearrangements or abnormal transcription . They are one of the major drivers behind cancer initiation and progression. Gene fusion can be used in the diagnosis of a variety of cancers. In 2018 November, the FDA approved the first tumor agnostic treatment for those with TRK fusion based on the clinical benefits observed across numerous tumor types. In some cancer types, fusion genes play very important roles, for example, over 10% fusion genes were found in NSCLC and over 15% were found in Thyroid cancer. ACTFusion™ is a targeted, multi-biomarker assay that enables you to examine 31 druggable fusion genes and182 transcripts, that are either included in the NCCN guidelines (e.g. ALK, ROS1, NTRK1/2/3) or tested in the global clinical trials (e.g. RET, MET, NRG1). 




Image title

ACTFusion™  Hallmark

  1. For All Solid Tumors

    Choose suitable treatment options based on fusion gene status 
  2. Treatment Types

    Targeted therapies approved by U.S. FDA and in the global clinical trials

Suammry of ACTFusion™ 

  1. Comprehensive Testing for  More Treatment Options

    A targeted, multi-biomarker assay that enables you to examine multiple druggable fusion genes across solid tumors, that are either included in the NCCN guidelines (e.g. ALK, ROS1, NTRK1/2/3) or tested in the global clinical trials (e.g. RET, MET, NRG1).
  2. Pioneering Bioinformatics

    Integration of cancer biology, medical informatics, molecular biology, cell biology, immunology, bioinformatics, data science and pharmaceutical biology to provide insightful interpretation
  3. Short Turnaround Time

    Providing professional solutions within  14 calendar days    (starting from the day qualified specimen is received at lab)
  4.  Report Consultation

    Every report is complemented with a face-to-face consultation with our medical team.

Technical Specification

Sample Types

FFPE

.5-20 unstained sections (10µm/slide)

.1H&E stained slide (5µm)


*Cell block from pleural effusion, ascites or pericardial hydrops (≥1X106cells)



Targeted Therapy Evaluation

eg.  ALK、 ROS1 、NTRK related fusion 

genes


Next Generation Sequencing  

31 fusion genes

182 fusion transcripts




* Pleural effusion, ascties or pericardial hydrops samples need to be processed into cell blocks before sending to ACT Genomics.